XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma

Sponsor
Anhui Provincial Hospital
Study ID
NCT03599778
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • Gastric Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To observe and evaluate the efficacy and safety of oxaliplatin with oapecitabine（XELOX）combined with apatinib as post-operative chemotherapy in locally advanced gastric adenocarcinoma with D2 dissection

Key Dates

Start date
Sep 1, 2018
Status verified
Jul 2018
Primary completion
Jan 30, 2025
Completion
Jan 30, 2025

Study Design

Enrollment
52 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: treatment group
    8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w) + apatinib'MTD(maximum tolerated dose)
  • Active Comparator: Control group
    8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w)

Primary Outcome Measure

Disease-free survival (DFS) [ Time Frame: 3 months ]

Central Contacts

Related Studies